Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

被引:39
|
作者
Adashek, Jacob J. [1 ]
Jain, Rohit K. [2 ]
Zhang, Jingsong [2 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
PARP inhibitors; DNA damage repair deficiency; prostate cancer; targeted therapy; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; MAINTENANCE THERAPY; OVARIAN-CANCER; MUTANT-CELLS; OLAPARIB; NIRAPARIB; DEFECTS; TUMORS; BRCA2;
D O I
10.3390/cells8080860
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate cancer. There is an unmet need to develop novel therapies beyond targeting AR signaling for metastatic castration-resistant prostate cancer (mCRPC). Poly (ADP-ribose) polymerase inhibitors (PARPi) belong to a class of targeted agents being developed for the treatment of homologous recombination repair (HRR) deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in early phase trials as a monotherapy for HRR-deficient mCRPC. Among them, olaparib and rucaparib have breakthrough designations for BRCA1/2-mutated mCRPC. Phase II studies also reported clinical activity of the PARPi and abiraterone combination and the PARPi checkpoint inhibitor combination in HRR-intact mCRPC. Ongoing phase III trials are testing these combinations as frontline or later line treatments for mCRPC. This review summarizes the critical clinical data as well as ongoing clinical trials for developing PARPi in treating mCRPC.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
    Zhao, Jinge
    Tang, Bo
    Shen, Pengfei
    Zeng, Hao
    Wei, Qiang
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 210
  • [32] The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations
    Teply, Benjamin A.
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (11) : 1293 - 1304
  • [33] Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Zobniw, Chrystia M.
    Causebrook, Alanna
    Fong, Mei Ka
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 97 - 105
  • [34] Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer
    Al-Mansouri, Loma
    Gurney, Howard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (06) : 288 - 295
  • [35] Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary
    Stein, Cy A.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : 407 - 409
  • [36] Novel Strategies for Treating Castration-Resistant Prostate Cancer
    Leung, David Ka-Wai
    Chiu, Peter Ka-Fung
    Ng, Chi-Fai
    Teoh, Jeremy Yuen-Chun
    BIOMEDICINES, 2021, 9 (04)
  • [37] Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
    Wu, Zixi
    Zhang, Junbiao
    Li, Le
    Wang, Zhihua
    Yang, Chunguang
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [38] Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
    Tsao, Che-Kai
    Seng, Sonia
    Oh, William K.
    Galsky, Matthew D.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 163 - 169
  • [39] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [40] Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
    de la Maza, Maria Dolores Fenor
    Chandran, Khobe
    Rekowski, Jan
    Shui, Irene M.
    Gurel, Bora
    Cross, Emily
    Carreira, Suzanne
    Yuan, Wei
    Westaby, Daniel
    Miranda, Susana
    Ferreira, Ana
    Seed, George
    Crespo, Mateus
    Figueiredo, Ines
    Bertan, Claudia
    Gil, Veronica
    Riisnaes, Ruth
    Sharp, Adam
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Tunariu, Nina
    Liu, Xiao Qiao
    Cristescu, Razvan
    Schloss, Charles
    Yap, Christina
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 659 - 667